Cargando…

Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study

OBJECTIVE: To report the primary (1‐year) results from PREVENT, the first phase III study evaluating secukinumab in patients with active nonradiographic axial spondyloarthritis (SpA). METHODS: A total of 555 patients were randomized (1:1:1) to receive subcutaneous secukinumab 150 mg with a loading d...

Descripción completa

Detalles Bibliográficos
Autores principales: Deodhar, Atul, Blanco, Ricardo, Dokoupilová, Eva, Hall, Stephen, Kameda, Hideto, Kivitz, Alan J., Poddubnyy, Denis, van de Sande, Marleen, Wiksten, Anna S., Porter, Brian O., Richards, Hanno B., Haemmerle, Sibylle, Braun, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839589/
https://www.ncbi.nlm.nih.gov/pubmed/32770640
http://dx.doi.org/10.1002/art.41477
_version_ 1783643416795545600
author Deodhar, Atul
Blanco, Ricardo
Dokoupilová, Eva
Hall, Stephen
Kameda, Hideto
Kivitz, Alan J.
Poddubnyy, Denis
van de Sande, Marleen
Wiksten, Anna S.
Porter, Brian O.
Richards, Hanno B.
Haemmerle, Sibylle
Braun, Jürgen
author_facet Deodhar, Atul
Blanco, Ricardo
Dokoupilová, Eva
Hall, Stephen
Kameda, Hideto
Kivitz, Alan J.
Poddubnyy, Denis
van de Sande, Marleen
Wiksten, Anna S.
Porter, Brian O.
Richards, Hanno B.
Haemmerle, Sibylle
Braun, Jürgen
author_sort Deodhar, Atul
collection PubMed
description OBJECTIVE: To report the primary (1‐year) results from PREVENT, the first phase III study evaluating secukinumab in patients with active nonradiographic axial spondyloarthritis (SpA). METHODS: A total of 555 patients were randomized (1:1:1) to receive subcutaneous secukinumab 150 mg with a loading dose (loading dose [LD] group), secukinumab 150 mg without a loading dose (non–loading dose [NL] group), or placebo weekly and then every 4 weeks starting at week 4. The NL group received placebo at weeks 1, 2, and 3 to maintain blinding. Switch to open‐label secukinumab or standard of care was permitted after week 20. The study had 2 independent analysis plans, per European Union and non‐US (plan A; week 16) and US (plan B; week 52) regulatory requirements. The primary end point was 40% improvement in disease activity according to the Assessment of SpondyloArthritis international Society (ASAS40) criteria at week 16 (in the LD group) and at week 52 (in the NL group) in tumor necrosis factor inhibitor (TNFi)–naive patients. Safety analyses included all patients who received ≥1 dose of study treatment. RESULTS: Overall, 481 patients completed 52 weeks of treatment, including 84.3% (156 of 185) in the LD group, 89.7% (165 of 184) in the NL group, and 86.0% (160 of 186) in the placebo group. The proportion of patients who switched to open‐label or standard of care between weeks 20 and 48 was 50.8% in the LD group, 47.3% in the NL group, and 64.0% in the placebo group. Both primary and all secondary end points were met at week 16. The proportion of TNFi‐naive patients who met ASAS40 was significantly higher for LD at week 16 (41.5%) and NL at week 52 (39.8%) versus placebo (29.2% at week 16 and 19.9% at week 52; both P < 0.05). No new safety findings were reported. CONCLUSION: Our findings indicate that secukinumab 150 mg provides significant and sustained improvement in signs and symptoms of nonradiographic axial SpA through 52 weeks. Safety was consistent with previous reports.
format Online
Article
Text
id pubmed-7839589
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-78395892021-02-01 Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study Deodhar, Atul Blanco, Ricardo Dokoupilová, Eva Hall, Stephen Kameda, Hideto Kivitz, Alan J. Poddubnyy, Denis van de Sande, Marleen Wiksten, Anna S. Porter, Brian O. Richards, Hanno B. Haemmerle, Sibylle Braun, Jürgen Arthritis Rheumatol Spondyloarthritis OBJECTIVE: To report the primary (1‐year) results from PREVENT, the first phase III study evaluating secukinumab in patients with active nonradiographic axial spondyloarthritis (SpA). METHODS: A total of 555 patients were randomized (1:1:1) to receive subcutaneous secukinumab 150 mg with a loading dose (loading dose [LD] group), secukinumab 150 mg without a loading dose (non–loading dose [NL] group), or placebo weekly and then every 4 weeks starting at week 4. The NL group received placebo at weeks 1, 2, and 3 to maintain blinding. Switch to open‐label secukinumab or standard of care was permitted after week 20. The study had 2 independent analysis plans, per European Union and non‐US (plan A; week 16) and US (plan B; week 52) regulatory requirements. The primary end point was 40% improvement in disease activity according to the Assessment of SpondyloArthritis international Society (ASAS40) criteria at week 16 (in the LD group) and at week 52 (in the NL group) in tumor necrosis factor inhibitor (TNFi)–naive patients. Safety analyses included all patients who received ≥1 dose of study treatment. RESULTS: Overall, 481 patients completed 52 weeks of treatment, including 84.3% (156 of 185) in the LD group, 89.7% (165 of 184) in the NL group, and 86.0% (160 of 186) in the placebo group. The proportion of patients who switched to open‐label or standard of care between weeks 20 and 48 was 50.8% in the LD group, 47.3% in the NL group, and 64.0% in the placebo group. Both primary and all secondary end points were met at week 16. The proportion of TNFi‐naive patients who met ASAS40 was significantly higher for LD at week 16 (41.5%) and NL at week 52 (39.8%) versus placebo (29.2% at week 16 and 19.9% at week 52; both P < 0.05). No new safety findings were reported. CONCLUSION: Our findings indicate that secukinumab 150 mg provides significant and sustained improvement in signs and symptoms of nonradiographic axial SpA through 52 weeks. Safety was consistent with previous reports. John Wiley and Sons Inc. 2020-11-24 2021-01 /pmc/articles/PMC7839589/ /pubmed/32770640 http://dx.doi.org/10.1002/art.41477 Text en © 2020 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Spondyloarthritis
Deodhar, Atul
Blanco, Ricardo
Dokoupilová, Eva
Hall, Stephen
Kameda, Hideto
Kivitz, Alan J.
Poddubnyy, Denis
van de Sande, Marleen
Wiksten, Anna S.
Porter, Brian O.
Richards, Hanno B.
Haemmerle, Sibylle
Braun, Jürgen
Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study
title Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study
title_full Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study
title_fullStr Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study
title_full_unstemmed Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study
title_short Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study
title_sort improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo‐controlled phase iii study
topic Spondyloarthritis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839589/
https://www.ncbi.nlm.nih.gov/pubmed/32770640
http://dx.doi.org/10.1002/art.41477
work_keys_str_mv AT deodharatul improvementofsignsandsymptomsofnonradiographicaxialspondyloarthritisinpatientstreatedwithsecukinumabprimaryresultsofarandomizedplacebocontrolledphaseiiistudy
AT blancoricardo improvementofsignsandsymptomsofnonradiographicaxialspondyloarthritisinpatientstreatedwithsecukinumabprimaryresultsofarandomizedplacebocontrolledphaseiiistudy
AT dokoupilovaeva improvementofsignsandsymptomsofnonradiographicaxialspondyloarthritisinpatientstreatedwithsecukinumabprimaryresultsofarandomizedplacebocontrolledphaseiiistudy
AT hallstephen improvementofsignsandsymptomsofnonradiographicaxialspondyloarthritisinpatientstreatedwithsecukinumabprimaryresultsofarandomizedplacebocontrolledphaseiiistudy
AT kamedahideto improvementofsignsandsymptomsofnonradiographicaxialspondyloarthritisinpatientstreatedwithsecukinumabprimaryresultsofarandomizedplacebocontrolledphaseiiistudy
AT kivitzalanj improvementofsignsandsymptomsofnonradiographicaxialspondyloarthritisinpatientstreatedwithsecukinumabprimaryresultsofarandomizedplacebocontrolledphaseiiistudy
AT poddubnyydenis improvementofsignsandsymptomsofnonradiographicaxialspondyloarthritisinpatientstreatedwithsecukinumabprimaryresultsofarandomizedplacebocontrolledphaseiiistudy
AT vandesandemarleen improvementofsignsandsymptomsofnonradiographicaxialspondyloarthritisinpatientstreatedwithsecukinumabprimaryresultsofarandomizedplacebocontrolledphaseiiistudy
AT wikstenannas improvementofsignsandsymptomsofnonradiographicaxialspondyloarthritisinpatientstreatedwithsecukinumabprimaryresultsofarandomizedplacebocontrolledphaseiiistudy
AT porterbriano improvementofsignsandsymptomsofnonradiographicaxialspondyloarthritisinpatientstreatedwithsecukinumabprimaryresultsofarandomizedplacebocontrolledphaseiiistudy
AT richardshannob improvementofsignsandsymptomsofnonradiographicaxialspondyloarthritisinpatientstreatedwithsecukinumabprimaryresultsofarandomizedplacebocontrolledphaseiiistudy
AT haemmerlesibylle improvementofsignsandsymptomsofnonradiographicaxialspondyloarthritisinpatientstreatedwithsecukinumabprimaryresultsofarandomizedplacebocontrolledphaseiiistudy
AT braunjurgen improvementofsignsandsymptomsofnonradiographicaxialspondyloarthritisinpatientstreatedwithsecukinumabprimaryresultsofarandomizedplacebocontrolledphaseiiistudy